Title: SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.

Journal: Toxicology and applied pharmacology20171015

Title: A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.

Journal: European journal of pharmacology20121205

Title: Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders20121201

Title: One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment.

Journal: Diabetes, obesity & metabolism20121101

Title: Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.

Journal: Journal of clinical pharmacology20121001

Title: Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.

Journal: Diabetes care20121001

Title: Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?

Journal: Diabetes technology & therapeutics20121001

Title: Recent advances in incretin-based therapies.

Journal: Clinical endocrinology20121001

Title: Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.

Journal: Diabetes & metabolism20121001

Title: DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.

Journal: Journal of molecular endocrinology20121001

Title: Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.

Journal: The Journal of clinical endocrinology and metabolism20121001

Title: Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.

Journal: Bioorganic & medicinal chemistry20121001

Title: Linagliptin as add-on therapy for type 2 diabetes - an overview.

Journal: Drugs of today (Barcelona, Spain : 1998)20121001

Title: Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences20120929

Title: Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.

Journal: European journal of pharmacology20120915

Title: Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.

Journal: World journal of diabetes20120915

Title: DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury.

Journal: American journal of physiology. Renal physiology20120901

Title: Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression.

Journal: Peptides20120901

Title: The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.

Journal: Journal of clinical pharmacy and therapeutics20120801

Title: Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

Journal: Diabetes, obesity & metabolism20120801

Title: GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.

Journal: Current clinical pharmacology20120801

Title: Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet.

Journal: Endocrinology20120801

Title: Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

Journal: Clinical pharmacokinetics20120801

Title: Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models.

Journal: Acta pharmacologica Sinica20120801

Title: Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice.

Journal: Metabolism: clinical and experimental20120701

Title: The incretin hormones: from scientific discovery to practical therapeutics.

Journal: Diabetologia20120701

Title: Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats.

Journal: International journal of cardiology20120628

Title: Nutrient detection by incretin hormone secreting cells.

Journal: Physiology & behavior20120606

Title: Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.

Journal: Journal of diabetes20120601

Title: Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.

Journal: Expert opinion on pharmacotherapy20120601

Title: Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.

Journal: Diabetes technology & therapeutics20120601

Title: Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.

Journal: Clinical therapeutics20120601

Title: Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.

Journal: Bioorganic & medicinal chemistry letters20120515

Title: CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation.

Journal: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery20120501

Title: An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.

Journal: Current diabetes reviews20120501

Title: High-performance liquid chromatography quadrupole time-of-flight mass spectrometry method for the analysis of antidiabetic drugs in aqueous environmental samples.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences20120501

Title: Stability-indicating RP-LC method for the determination of vildagliptin and mass spectrometry detection for a main degradation product.

Journal: Journal of chromatographic science20120501

Title: Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences20120411

Title: DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

Journal: Diabetes & metabolism20120401

Title: Dipeptidyl peptidase-4 inhibitors: 3 years of experience.

Journal: Diabetes technology & therapeutics20120401

Title: Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13(3): 193-203.

Journal: Diabetes, obesity & metabolism20120401

Title: Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.

Journal: Diabetes, obesity & metabolism20120401

Title: Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes.

Journal: International journal of clinical pharmacology and therapeutics20120401

Title: Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and β-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet.

Journal: Endocrinology20120301

Title: Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.

Journal: The Annals of pharmacotherapy20120301

Title: Clinical pharmacokinetics and pharmacodynamics of vildagliptin.

Journal: Clinical pharmacokinetics20120301

Title: Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide.

Journal: Minerva endocrinologica20120301

Title: Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.

Journal: British journal of clinical pharmacology20120301

Title: Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.

Journal: British journal of clinical pharmacology20120301

Title: Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus.

Journal: Indian journal of endocrinology and metabolism20120301

Title: Pleiotropic effects of incretins.

Journal: Indian journal of endocrinology and metabolism20120301

Title: Stability and bioactivity studies on dipeptidyl peptidase IV resistant glucogan-like peptide-1 analogues.

Journal: Protein and peptide letters20120201

Title: Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy.

Journal: The Journal of pharmacology and experimental therapeutics20120101

Title: Diabetes: impaired damage control.

Journal: Diabetologia20120101

Title: A review of gliptins in 2011.

Journal: Expert opinion on pharmacotherapy20120101

Title: DPP-4 inhibitors and lipids: systematic review and meta-analysis.

Journal: Advances in therapy20120101

Title: Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.

Journal: Cardiovascular diabetology20120101

Title: Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.

Journal: Cardiovascular diabetology20120101

Title: Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity.

Journal: Gut and liver20120101

Title: Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neurons.

Journal: BMC gastroenterology20120101

Title: Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.

Journal: BMC pharmacology20120101

Title: Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats.

Journal: PloS one20120101

Title: Uncovering undetected hypoglycemic events.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20120101

Title: Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20120101

Title: Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.

Journal: Experimental diabetes research20120101

Title: Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis.

Journal: ISRN endocrinology20120101

Title: Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.

Journal: Journal of diabetes and its complications20120101

Title: Red carpeting the newer antidiabetics.

Journal: Journal of pharmacology & pharmacotherapeutics20120101

Title: The management of type 2 diabetic patients with hypoglycaemic agents.

Journal: ISRN endocrinology20120101

Title: Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20120101

Title: Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus.

Journal: Vascular health and risk management20120101

Title: Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease.

Journal: Cardiovascular diabetology20120101

Title: Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).

Journal: Cardiovascular diabetology20120101

Title: Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory Activity.

Journal: PloS one20120101

Title: Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease.

Journal: Internal medicine (Tokyo, Japan)20120101

Title: Impact of diabetes on postinfarction heart failure and left ventricular remodeling.

Journal: Current heart failure reports20111201

Title: [Incretin-based therapy for treating patients with type 2 diabetes].

Journal: Orvosi hetilap20111127

Title: Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222.

Journal: Xenobiotica; the fate of foreign compounds in biological systems20111101

Title: The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.

Journal: International journal of clinical practice20111101

Title: Tolerability of dipeptidyl peptidase-4 inhibitors: a review.

Journal: Clinical therapeutics20111101

Title: Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.

Journal: Current medical research and opinion20111101

Title: Emerging role of DPP-4 inhibitor Vildagliptin in the management of type-2 diabetes.

Journal: The Journal of the Association of Physicians of India20111101

Title: Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial.

Journal: Diabetes, obesity & metabolism20111001

Title: Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice.

Journal: Diabetologia20111001

Title: Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients.

Journal: Diabetes & metabolism journal20111001

Title: 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.

Journal: Bioorganic & medicinal chemistry20110915

Title: [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].

Journal: Orvosi hetilap20110911

Title: Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.

Journal: Diabetes, obesity & metabolism20110901

Title: The metabolic syndrome influences the response to incretin-based therapies.

Journal: Acta diabetologica20110901

Title: Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes.

Journal: Diabetes care20110901

Title: Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.

Journal: Recent patents on endocrine, metabolic & immune drug discovery20110901

Title: Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.

Journal: Current diabetes reviews20110901

Title: Emerging role of insulin with incretin therapies for management of type 2 diabetes.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders20110901

Title: Enhanced glycemic control with combination therapy for type 2 diabetes in primary care.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders20110901

Title: Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?

Journal: Journal of medicinal chemistry20110825

Title: Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial.

Journal: Diabetologia20110801

Title: Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs.

Journal: Diabetologia20110801

Title: Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions.

Journal: Clinical & experimental metastasis20110801

Title: Vildagliptin in the treatment of type 2 diabetes mellitus.

Journal: Expert opinion on pharmacotherapy20110801

Title: Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.

Journal: Expert opinion on drug discovery20110801

Title: Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

Journal: Drugs20110730

Title: Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.

Journal: Diabetes, obesity & metabolism20110701

Title: Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.

Journal: Current medical research and opinion20110701

Title: Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.

Journal: Current medical research and opinion20110701

Title: Noninsulin pharmacological management of type 1 diabetes mellitus.

Journal: Indian journal of endocrinology and metabolism20110701

Title: Health economic evaluation of dipeptidyl peptidase-4 inhibitors.

Journal: Indian journal of endocrinology and metabolism20110701

Title: Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea.

Journal: Arquivos brasileiros de endocrinologia e metabologia20110601

Title: An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.

Journal: Contemporary clinical trials20110501

Title: Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.

Journal: Pharmacological research20110501

Title: Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.

Journal: Diabetes20110501

Title: DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.

Journal: Diabetes care20110501

Title: [Vildagliptin].

Journal: Nihon rinsho. Japanese journal of clinical medicine20110501

Title: [Emerging GLP-1 analogues and dipeptidyl peptidase 4(DPP-4) inhibitors].

Journal: Nihon rinsho. Japanese journal of clinical medicine20110501

Title: Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.

Journal: Clinical therapeutics20110501

Title: Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders20110501

Title: Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders20110501

Title: Pro-soft Val-boroPro: a strategy for enhancing in vivo performance of boronic acid inhibitors of serine proteases.

Journal: Journal of medicinal chemistry20110414

Title: Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

Journal: Diabetes, obesity & metabolism20110401

Title: Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.

Journal: Diabetes, obesity & metabolism20110401

Title: Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as 'isoglycemic' intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.

Journal: The Journal of clinical endocrinology and metabolism20110401

Title: Simultaneous identification and validated quantification of 11 oral hypoglycaemic drugs in plasma by electrospray ionisation liquid chromatography-mass spectrometry.

Journal: Analytical and bioanalytical chemistry20110401

Title: GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes.

Journal: Diabetes20110401

Title: Understanding the incretin effect.

Journal: The Journal of clinical endocrinology and metabolism20110401

Title: [Incretin therapy and the metabolic syndrome].

Journal: Vnitrni lekarstvi20110401

Title: Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity.

Journal: Diabetes & metabolism journal20110401

Title: Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus.

Journal: Diabetes & metabolism journal20110401

Title: Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.

Journal: The Journal of the Association of Physicians of India20110401

Title: Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues.

Journal: Journal of medicinal chemistry20110324

Title: Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.

Journal: Diabetes, obesity & metabolism20110301

Title: Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.

Journal: Diabetes, obesity & metabolism20110301

Title: Type 2 diabetes: uses of thiazolidinediones and insulin.

Journal: Diabetes care20110201

Title: Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.

Journal: Diabetes care20110201

Title: Alogliptin for the treatment of type 2 diabetes.

Journal: Drugs of today (Barcelona, Spain : 1998)20110201

Title: Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.

Journal: Hospital practice (1995)20110201

Title: Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.

Journal: Prescrire international20110201

Title: The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats.

Journal: European journal of pharmacology20110115

Title: The dipeptidyl peptidase IV (CD26, EC 3.4.14.5) inhibitor vildagliptin is a potent antihyperalgesic in rats by promoting endomorphin-2 generation in the spinal cord.

Journal: European journal of pharmacology20110110

Title: Advances in the treatment of type 2 diabetes mellitus.

Journal: American journal of therapeutics20110101

Title: Weight considerations in pharmacotherapy for type 2 diabetes.

Journal: Journal of obesity20110101

Title: Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials.

Journal: Diabetes, obesity & metabolism20110101

Title: Understanding diabetes in patients with HIV/AIDS.

Journal: Diabetology & metabolic syndrome20110101

Title: Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study.

Journal: Cardiovascular diabetology20110101

Title: Vildagliptin-induced acute pancreatitis.

Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists20110101

Title: Comments on the article 'Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations' by Marfella et al.: (Journal of Diabetes and Its Complications 24 [2010] 79-83).

Journal: Journal of diabetes and its complications20110101

Title: Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies.

Journal: Vascular health and risk management20110101

Title: Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series.

Journal: Journal of medical case reports20110101

Title: [Plasmapheresis as treatment for severe hypertriglyceridemia].

Journal: Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion20110101

Title: Sensing via intestinal sweet taste pathways.

Journal: Frontiers in neuroscience20110101

Title: Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control.

Journal: PloS one20110101

Title: Incretin-based therapy and pancreatitis-what is the risk?

Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists20110101

Title: Diabetes and Ramadan: an update on use of glycemic therapies during fasting.

Journal: Annals of Saudi medicine20110101

Title: Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines.

Journal: Indian journal of endocrinology and metabolism20110101

Title: Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins.

Journal: Cardiovascular diabetology20110101

Title: Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function.

Journal: Experimental diabetes research20110101

Title: From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.

Journal: Experimental diabetes research20110101

Title: New onset diabetes after transplantation (NODAT): an overview.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20110101

Title: Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

Journal: The open cardiovascular medicine journal20110101

Title: Reply to the 'Comments on the article 'Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations'', by Avogaro (Journal of Diabetes and Its Complications 25 [2011] 352-353).

Journal: Journal of diabetes and its complications20110101

Title: Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20110101

Title: Postnatal development of numbers and mean sizes of pancreatic islets and beta-cells in healthy mice and GIPR(dn) transgenic diabetic mice.

Journal: PloS one20110101

Title: Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.

Journal: Clinical drug investigation20110101

Title: Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.

Journal: Experimental diabetes research20110101

Title: The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.

Journal: Endocrine journal20110101

Title: Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.

Journal: Cardiovascular diabetology20110101

Title: Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.

Journal: The open medicinal chemistry journal20110101

Title: Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.

Journal: Journal of pharmacology & pharmacotherapeutics20110101

Title: South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.

Journal: Indian journal of endocrinology and metabolism20110101

Title: Choosing a gliptin.

Journal: Indian journal of endocrinology and metabolism20110101

Title: Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.

Journal: Open medicine : a peer-reviewed, independent, open-access journal20110101

Title: Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.

Journal: PloS one20110101

Title: Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.

Journal: Cardiovascular diabetology20110101

Title: Molecular determinants of magnolol targeting both RXRα and PPARγ.

Journal: PloS one20110101

Title: [Characterization of patients with type 2 diabetes treated with vildagliptin].

Journal: Acta medica portuguesa20110101

Title: A time-resolved fluorescence probe for dipeptidyl peptidase 4 and its application in inhibitor screening.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)20101203

Title: Fewer major amputations among individuals with diabetes in Finland in 1997-2007: a population-based study.

Journal: Diabetes care20101201

Title: Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus.

Journal: Korean diabetes journal20101201

Title: Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders20101201

Title: Efficacy and safety of vildagliptin/pioglitazone combination therapy in Korean patients with diabetes.

Journal: World journal of diabetes20101115

Title: Vildagliptin: a review of its use in type 2 diabetes mellitus.

Journal: Drugs20101112

Title: Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study.

Journal: Diabetes research and clinical practice20101101

Title: DPP-4 inhibitors: what may be the clinical differentiators?

Journal: Diabetes research and clinical practice20101101

Title: Multidrug therapy in a patient with Rabson-Mendenhall syndrome.

Journal: Diabetologia20101101

Title: Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.

Journal: Diabetes care20101101

Title: Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus.

Journal: Current diabetes reviews20101101

Title: [Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica20101101

Title: Gateways to clinical trials.

Journal: Methods and findings in experimental and clinical pharmacology20101101

Title: SLCO1B1 polymorphism and oral antidiabetic drugs.

Journal: Basic & clinical pharmacology & toxicology20101001

Title: Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes.

Journal: Diabetologia20101001

Title: Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats.

Journal: Diabetes20101001

Title: Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.

Journal: Expert opinion on drug metabolism & toxicology20101001

Title: Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats.

Journal: Xenobiotica; the fate of foreign compounds in biological systems20101001

Title: Liraglutide: effects beyond glycaemic control in diabetes treatment.

Journal: International journal of clinical practice. Supplement20101001

Title: Sitagliptin-induced hemolysis.

Journal: Indian journal of pharmacology20101001

Title: Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.

Journal: The American journal of geriatric pharmacotherapy20101001

Title: Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein.

Journal: Journal of medicinal chemistry20100923

Title: Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus.

Journal: Diabetes research and clinical practice20100901

Title: Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats.

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme20100901

Title: Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.

Journal: Diabetes, obesity & metabolism20100901

Title: Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.

Journal: Clinical pharmacokinetics20100901

Title: Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study.

Journal: Diabetes care20100901

Title: Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.

Journal: International journal of clinical pharmacology and therapeutics20100901

Title: [Importance of daily glycemic variability in achieving glycemic targets in type 2 diabetes: role of DPP-4 inhibitors].

Journal: Medicina clinica20100901

Title: The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis.

Journal: Diabetes care20100801

Title: Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme20100801

Title: Managing type 2 diabetes in the primary care setting: beyond glucocentricity.

Journal: The American journal of the medical sciences20100801

Title: Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.

Journal: Diabetes, obesity & metabolism20100801

Title: Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study.

Journal: Diabetes, obesity & metabolism20100801

Title: Recommendations for management of diabetes during Ramadan: update 2010.

Journal: Diabetes care20100801

Title: Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals.

Journal: Indian journal of pharmacology20100801

Title: The evolving place of incretin-based therapies in type 2 diabetes.

Journal: Pediatric nephrology (Berlin, Germany)20100701

Title: Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis.

Journal: Diabetologia20100701

Title: Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.

Journal: Current medical research and opinion20100701

Title: Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.

Journal: Arteriosclerosis, thrombosis, and vascular biology20100701

Title: Taking aim at islet hormones with GLP-1: is insulin or glucagon the better target?

Journal: Diabetes20100701

Title: Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.

Journal: British journal of clinical pharmacology20100701

Title: Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Journal: Health technology assessment (Winchester, England)20100701

Title: (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.

Journal: Bioorganic & medicinal chemistry letters20100615

Title: Synthesis and biological evaluation of azobicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes.

Journal: Bioorganic & medicinal chemistry letters20100615

Title: Synthesis and biological evaluation of bicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes.

Journal: Bioorganic & medicinal chemistry letters20100615

Title: Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses.

Journal: Cell metabolism20100609

Title: Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

Journal: International journal of clinical practice20100601

Title: Diabesity: therapeutic options.

Journal: Diabetes, obesity & metabolism20100601

Title: Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population.

Journal: Diabetes, obesity & metabolism20100601

Title: An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials.

Journal: Diabetes, obesity & metabolism20100601

Title: Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.

Journal: Pharmacotherapy20100501

Title: Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice.

Journal: Diabetes, obesity & metabolism20100501

Title: Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

Journal: Diabetes20100501

Title: Graphic rule for drug metabolism systems.

Journal: Current drug metabolism20100501

Title: [New hypoglycemic agents in type 2 diabetes].

Journal: La Revue du praticien20100420

Title: Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.

Journal: Diabetes care20100401

Title: Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.

Journal: Diabetes20100401

Title: Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.

Journal: Diabetes, obesity & metabolism20100401

Title: Effect of vildagliptin as add-on therapy to a low-dose metformin.

Journal: World journal of diabetes20100315

Title: ASP4000, a slow-binding dipeptidyl peptidase 4 inhibitor, has antihyperglycemic activity of long duration in Zucker fatty rats.

Journal: Acta diabetologica20100301

Title: [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].

Journal: Pharmazie in unserer Zeit20100301

Title: A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.

Journal: Diabetic medicine : a journal of the British Diabetic Association20100301

Title: Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.

Journal: Regulatory peptides20100225

Title: Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors.

Journal: ChemMedChem20100201

Title: Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.

Journal: Diabetes care20100201

Title: Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs.

Journal: Journal of medicinal chemistry20100128

Title: Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations.

Journal: Journal of diabetes and its complications20100101

Title: The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.

Journal: Diabetes technology & therapeutics20100101

Title: Clinical approaches to preserve beta-cell function in diabetes.

Journal: Advances in experimental medicine and biology20100101

Title: [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].

Journal: Nederlands tijdschrift voor geneeskunde20100101

Title: Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.

Journal: BMC endocrine disorders20100101

Title: Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.

Journal: Vascular health and risk management20100101

Title: Rhinorrhea, cough and fatigue in patients taking sitagliptin.

Journal: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology20100101

Title: Forecasting drug utilization and expenditure in a metropolitan health region.

Journal: BMC health services research20100101

Title: Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes.

Journal: Therapeutics and clinical risk management20100101

Title: Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Journal: BMC health services research20100101

Title: Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society.

Journal: Diabetology & metabolic syndrome20100101

Title: A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.

Journal: Pharmacology20100101

Title: Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment--Lifestyle Over and Above Drugs in Diabetes (LOADD) study: randomised controlled trial.

Journal: BMJ (Clinical research ed.)20100101

Title: Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.

Journal: Vascular health and risk management20100101

Title: Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.

Journal: PloS one20100101

Title: Exenatide once weekly: clinical outcomes and patient satisfaction.

Journal: Patient preference and adherence20100101

Title: Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.

Journal: Vascular health and risk management20100101

Title: A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation.

Journal: Trials20100101

Title: Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

Journal: Core evidence20100101

Title: Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice.

Journal: PloS one20100101

Title: [The incretin effect and type 2 diabetes].

Journal: Revista medica del Instituto Mexicano del Seguro Social20100101

Title: Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20100101

Title: New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20100101

Title: Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20100101

Title: Optimizing weight control in diabetes: antidiabetic drug selection.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20100101

Title: Saxagliptin for type 2 diabetes.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20100101

Title: Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.

Journal: Drug, healthcare and patient safety20100101

Title: Managing insulin resistance: role of liraglutide.

Journal: Clinical pharmacology : advances and applications20100101

Title: Reporting of results of interventional studies by the information service of the National Institutes of Health.

Journal: Clinical pharmacology : advances and applications20100101

Title: Exercise therapy in type 2 diabetes.

Journal: Acta diabetologica20091201

Title: Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme20091201

Title: Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.

Journal: European journal of endocrinology20091201

Title: Vildagliptin in clinical practice: a review of literature.

Journal: Expert opinion on pharmacotherapy20091101

Title: Incretin-based therapies: viewpoints on the way to consensus.

Journal: Diabetes care20091101

Title: Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines.

Journal: Diabetes care20091101

Title: Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes.

Journal: Diabetes care20091101

Title: Obesity in the elderly diabetic patient: is weight loss beneficial? No.

Journal: Diabetes care20091101

Title: DPP-4 inhibitors in clinical practice.

Journal: Postgraduate medicine20091101

Title: A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.

Journal: Clinical therapeutics20091101

Title: Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

Journal: Pharmacology & therapeutics20091001

Title: Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.

Journal: Diabetes, obesity & metabolism20091001

Title: Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.

Journal: International journal of clinical practice20091001

Title: Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.

Journal: Archives of medical research20091001

Title: Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

Journal: Clinical science (London, England : 1979)20090928

Title: Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein.

Journal: The Journal of biological chemistry20090911

Title: The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.

Journal: Diabetes care20090901

Title: Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice.

Journal: Diabetes20090901

Title: Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema.

Journal: Hypertension (Dallas, Tex. : 1979)20090901

Title: Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema.

Journal: Hypertension (Dallas, Tex. : 1979)20090901

Title: The 6th Annual World Congress on the insulin resistance syndrome.

Journal: Diabetes care20090901

Title: Gateways to clinical trials.

Journal: Methods and findings in experimental and clinical pharmacology20090901

Title: Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.

Journal: European journal of medicinal chemistry20090801

Title: Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

Journal: Diabetes, obesity & metabolism20090801

Title: Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors.

Journal: Bioorganic & medicinal chemistry letters20090801

Title: Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).

Journal: Best practice & research. Clinical endocrinology & metabolism20090801

Title: Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.

Journal: Best practice & research. Clinical endocrinology & metabolism20090801

Title: Functional assessment of pancreatic beta-cell area in humans.

Journal: Diabetes20090701

Title: Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.

Journal: European journal of internal medicine20090701

Title: Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes.

Journal: Diabetes20090601

Title: Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus.

Journal: Diabetes, obesity & metabolism20090601

Title: Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.

Journal: The American journal of medicine20090601

Title: Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

Journal: Diabetes, obesity & metabolism20090601

Title: [Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].

Journal: Journal de pharmacie de Belgique20090601

Title: Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme20090501

Title: Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.

Journal: Diabetes, obesity & metabolism20090501

Title: Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes.

Journal: Current medical research and opinion20090501

Title: Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.

Journal: Diabetes, obesity & metabolism20090501

Title: The scientific evidence: vildagliptin and the benefits of islet enhancement.

Journal: Diabetes, obesity & metabolism20090501

Title: Translating science into clinical practice: focus on vildagliptin in combination with metformin.

Journal: Diabetes, obesity & metabolism20090501

Title: [The value of incretin based therapies].

Journal: Deutsche medizinische Wochenschrift (1946)20090501

Title: [Incretin related agents for treatment of diabetes mellitus].

Journal: Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine20090410

Title: Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.

Journal: The Journal of clinical endocrinology and metabolism20090401

Title: Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.

Journal: Bioorganic & medicinal chemistry letters20090401

Title: Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.

Journal: Diabetes20090401

Title: Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors.

Journal: Bioorganic & medicinal chemistry20090315

Title: New treatments in type 2 diabetes: a focus on the incretin-based therapies.

Journal: Clinical endocrinology20090301

Title: Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.

Journal: Drug metabolism and disposition: the biological fate of chemicals20090301

Title: Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.

Journal: Drug metabolism and disposition: the biological fate of chemicals20090301

Title: Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.

Journal: The Journal of clinical endocrinology and metabolism20090301

Title: Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.

Journal: Metabolism: clinical and experimental20090301

Title: Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.

Journal: Bioorganic & medicinal chemistry20090301

Title: Diabetes treatment.

Journal: Diabetes care20090301

Title: Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

Journal: Advances in therapy20090301

Title: [Vildagliptin (Galvus) and fixed combination vildagliptine-metformin (Eucreas) in the treatment of type 2 diabetes].

Journal: Revue medicale de Liege20090301

Title: Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models.

Journal: The Journal of pharmacology and experimental therapeutics20090201

Title: Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus.

Journal: Diabetes research and clinical practice20090201

Title: Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Journal: Diabetes, obesity & metabolism20090201

Title: Recent advances in antidiabetic drug therapies targeting the enteroinsular axis.

Journal: Current drug metabolism20090201

Title: Drug evaluation: vildagliptin-metformin single-tablet combination.

Journal: Advances in therapy20090201

Title: In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma.

Journal: Biochemical pharmacology20090115

Title: Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers.

Journal: Journal of clinical pharmacology20090101

Title: Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.

Journal: Diabetes20090101

Title: Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.

Journal: Diabetes care20090101

Title: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Journal: Diabetes care20090101

Title: Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

Journal: The Journal of clinical endocrinology and metabolism20090101

Title: Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.

Journal: Current drug targets20090101

Title: Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice.

Journal: Postgraduate medicine20090101

Title: Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes.

Journal: Postgraduate medicine20090101

Title: Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.

Journal: Mymensingh medical journal : MMJ20090101

Title: Postprandial hyperglycemia as an etiological factor in vascular failure.

Journal: Cardiovascular diabetology20090101

Title: Potential of liraglutide in the treatment of patients with type 2 diabetes.

Journal: Vascular health and risk management20090101

Title: Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis.

Journal: PloS one20090101

Title: A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.

Journal: Cardiovascular diabetology20090101

Title: Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.

Journal: Therapeutics and clinical risk management20090101

Title: Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Journal: Journal of the American Pharmacists Association : JAPhA20090101

Title: Diabetic nephropathy.

Journal: Diabetology & metabolic syndrome20090101

Title: Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.

Journal: Pharmacological reports : PR20090101

Title: Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion.

Journal: Journal of diabetes science and technology20090101

Title: Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin.

Journal: International journal of clinical practice20090101

Title: Gliptins: a new class of oral antidiabetic agents.

Journal: Indian journal of pharmaceutical sciences20090101

Title: Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20090101

Title: Alogliptin: a new addition to the class of DPP-4 inhibitors.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20090101

Title: Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20090101

Title: DPP4 inhibitors for diabetes--what next?

Journal: Biochemical pharmacology20081215

Title: Incretin-based therapies in type 2 diabetes: a review of clinical results.

Journal: Diabetes research and clinical practice20081215

Title: Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin.

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme20081201

Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.

Journal: Diabetes care20081201

Title: Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.

Journal: Expert opinion on emerging drugs20081201

Title: Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.

Journal: Acta bio-medica : Atenei Parmensis20081201

Title: Gateways to clinical trials. December 2008.

Journal: Methods and findings in experimental and clinical pharmacology20081201

Title: Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.

Journal: Vascular health and risk management20081201

Title: Vildagliptin: a new oral treatment for type 2 diabetes mellitus.

Journal: Vascular health and risk management20081201

Title: Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.

Journal: Diabetes, obesity & metabolism20081101

Title: The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.

Journal: Clinical endocrinology20081101

Title: Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia.

Journal: Diabetes, obesity & metabolism20081101

Title: Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited.

Journal: Diabetes, obesity & metabolism20081101

Title: Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.

Journal: Cardiology clinics20081101

Title: The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism.

Journal: Current diabetes reviews20081101

Title: [Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1].

Journal: MMW Fortschritte der Medizin20081030

Title: Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme20081001

Title: Incretin-based therapies in type 2 diabetes mellitus.

Journal: The Journal of clinical endocrinology and metabolism20081001

Title: [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].

Journal: Deutsche medizinische Wochenschrift (1946)20081001

Title: Recent advances in the management of type 2 diabetes mellitus: a review.

Journal: Postgraduate medical journal20081001

Title: Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.

Journal: Prescrire international20081001

Title: Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database.

Journal: Diabetes, obesity & metabolism20080901

Title: Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

Journal: Diabetes, obesity & metabolism20080801

Title: Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.

Journal: Arquivos brasileiros de endocrinologia e metabologia20080801

Title: RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes.

Journal: Diabetic medicine : a journal of the British Diabetic Association20080801

Title: Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.

Journal: Vascular health and risk management20080801

Title: Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.

Journal: Bioorganic & medicinal chemistry letters20080715

Title: Discovery of conformationally rigid 3-azabicyclo[3.1.0]hexane-derived dipeptidyl peptidase-IV inhibitors.

Journal: Bioorganic & medicinal chemistry letters20080715

Title: Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.

Journal: Current opinion in clinical nutrition and metabolic care20080701

Title: Beyond insulin replacement: addressing the additional needs of the diabetes patient.

Journal: Diabetes, obesity & metabolism20080701

Title: From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.

Journal: Current opinion in drug discovery & development20080701

Title: Three new drugs for type 2 diabetes.

Journal: Drug and therapeutics bulletin20080701

Title: DPP4 inhibitors: a new approach in diabetes treatment.

Journal: Advances in therapy20080701

Title: Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.

Journal: International journal of clinical pharmacology and therapeutics20080701

Title: Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus.

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme20080601

Title: Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers.

Journal: Current medical research and opinion20080601

Title: Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

Journal: Expert opinion on investigational drugs20080601

Title: Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes.

Journal: The AAPS journal20080601

Title: Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.

Journal: Vascular health and risk management20080601

Title: Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

Journal: Core evidence20080601

Title: Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?

Journal: Naunyn-Schmiedeberg's archives of pharmacology20080501

Title: Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.

Journal: Frontiers in bioscience : a journal and virtual library20080501

Title: Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects.

Journal: International journal of clinical pharmacology and therapeutics20080501

Title: Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

Journal: The Cochrane database of systematic reviews20080416

Title: (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.

Journal: The Journal of pharmacology and experimental therapeutics20080401

Title: Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.

Journal: Diabetic medicine : a journal of the British Diabetic Association20080401

Title: Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.

Journal: Vascular health and risk management20080401

Title: The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.

Journal: British journal of clinical pharmacology20080301

Title: Hypoglycaemia in Type 2 diabetes.

Journal: Diabetic medicine : a journal of the British Diabetic Association20080301

Title: Islet cell function is as interesting as insulin resistance for T2DM treatment options.

Journal: International journal of clinical practice. Supplement20080301

Title: The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.

Journal: International journal of clinical practice. Supplement20080301

Title: Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes.

Journal: International journal of clinical practice. Supplement20080301

Title: Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.

Journal: The Journal of clinical endocrinology and metabolism20080201

Title: Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.

Journal: Diabetes & metabolism20080201

Title: DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?

Journal: Diabetes & metabolism20080201

Title: The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

Journal: Diabetes care20080101

Title: Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia.

Journal: The Journal of clinical endocrinology and metabolism20080101

Title: Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

Journal: Diabetes care20080101

Title: Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.

Journal: Journal of clinical pharmacology20080101

Title: Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.

Journal: Diabetes, obesity & metabolism20080101

Title: Update: vildagliptin for the treatment of Type 2 diabetes.

Journal: Expert opinion on investigational drugs20080101

Title: Gateways to clinical trials.

Journal: Methods and findings in experimental and clinical pharmacology20080101

Title: Boc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice.

Journal: PloS one20080101

Title: Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.

Journal: Medscape journal of medicine20080101

Title: Vaccination against GIP for the treatment of obesity.

Journal: PloS one20080101

Title: Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.

Journal: The review of diabetic studies : RDS20080101

Title: New drugs for type 2 diabetes mellitus: what is their place in therapy?

Journal: Drugs20080101

Title: New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

Journal: Drugs & aging20080101

Title: Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.

Journal: BMC endocrine disorders20080101

Title: Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.

Journal: Drugs20080101

Title: Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.

Journal: Current topics in medicinal chemistry20080101

Title: The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus.

Journal: Indian journal of pharmacology20080101

Title: Commonality between diabetes and Alzheimer's disease and a new strategy for the therapy.

Journal: Clinical medicine. Pathology20080101

Title: [Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic].

Journal: Lakartidningen20071205

Title: Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.

Journal: Diabetes20071201

Title: Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy.

Journal: Diabetes care20071201

Title: Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects.

Journal: Current medical research and opinion20071201

Title: DPP-4 inhibitors.

Journal: Best practice & research. Clinical endocrinology & metabolism20071201

Title: Clinical management strategies for type 2 diabetes.

Journal: JAAPA : official journal of the American Academy of Physician Assistants20071201

Title: New treatments for type 2 diabetes--the DPP4 inhibitors.

Journal: Primary care diabetes20071201

Title: The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

Journal: The Journal of clinical endocrinology and metabolism20071101

Title: Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme20071101

Title: Gateways to clinical trials.

Journal: Methods and findings in experimental and clinical pharmacology20071101

Title: DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.

Journal: Regulatory peptides20071004

Title: GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

Journal: Current diabetes reports20071001

Title: Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes.

Journal: Diabetic medicine : a journal of the British Diabetic Association20070901

Title: Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.

Journal: Journal of clinical pharmacology20070901

Title: Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

Journal: Diabetes, obesity & metabolism20070901

Title: The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.

Journal: Diabetes, obesity & metabolism20070901

Title: Does addition of vildagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus?

Journal: Nature clinical practice. Endocrinology & metabolism20070801

Title: Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.

Journal: International journal of clinical practice. Supplement20070801

Title: Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.

Journal: International journal of clinical practice. Supplement20070801

Title: Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.

Journal: International journal of clinical practice. Supplement20070801

Title: Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.

Journal: Pharmacotherapy20070801

Title: Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers.

Journal: Journal of clinical pharmacology20070801

Title: Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

Journal: JAMA20070711

Title: The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.

Journal: European journal of clinical pharmacology20070701

Title: [New concepts in the treatment of type 2 diabetes].

Journal: Der Internist20070701

Title: A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.

Journal: Current medical research and opinion20070701

Title: Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.

Journal: Diabetes care20070601

Title: Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.

Journal: Diabetologia20070601

Title: Which patients are candidates for dipeptidyl peptidase IV inhibitors?

Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists20070601

Title: Vildagliptin: a novel oral therapy for type 2 diabetes mellitus.

Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists20070601

Title: New treatments for diabetes.

Journal: The New England journal of medicine20070524

Title: Dipeptidyl peptidase 8/9-like activity in human leukocytes.

Journal: Journal of leukocyte biology20070501

Title: Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

Journal: Diabetes20070501

Title: Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.

Journal: Journal of clinical pharmacology20070501

Title: The role of vildagliptin in the management of type 2 diabetes mellitus.

Journal: The Annals of pharmacotherapy20070501

Title: Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Journal: Current medical research and opinion20070501

Title: Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.

Journal: Diabetes research and clinical practice20070401

Title: The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

Journal: The Journal of clinical endocrinology and metabolism20070401

Title: Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

Journal: Diabetes care20070401

Title: beta-cell failure in diabetes and preservation by clinical treatment.

Journal: Endocrine reviews20070401

Title: [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].

Journal: Orvosi hetilap20070401

Title: Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.

Journal: Current medical research and opinion20070401

Title: Gateways to clinical trials.

Journal: Methods and findings in experimental and clinical pharmacology20070401

Title: [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].

Journal: Revue medicale de Liege20070401

Title: Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.

Journal: Vascular health and risk management20070401

Title: Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.

Journal: Current opinion in endocrinology, diabetes, and obesity20070401

Title: 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.

Journal: Bioorganic & medicinal chemistry letters20070301

Title: Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.

Journal: Diabetes, obesity & metabolism20070301

Title: Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

Journal: Diabetes, obesity & metabolism20070301

Title: Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

Journal: Diabetes, obesity & metabolism20070301

Title: Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme20070301

Title: Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

Journal: Diabetes care20070201

Title: Incretins: a new treatment option for type 2 diabetes?

Journal: The Netherlands journal of medicine20070201

Title: Gliptins.

Journal: Lancet (London, England)20070127

Title: Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.

Journal: Diabetes20070101

Title: Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes.

Journal: Journal of clinical pharmacology20070101

Title: The physiology of incretin hormones and the basis for DPP-4 inhibitors.

Journal: The Diabetes educator20070101

Title: Gateways to clinical trials.

Journal: Methods and findings in experimental and clinical pharmacology20070101

Title: 11 Years of cyanopyrrolidines as DPP-IV inhibitors.

Journal: Current topics in medicinal chemistry20070101

Title: Vildagliptin was noninferior to rosiglitazone for glycemic control in type 2 diabetes but caused less weight gain.

Journal: ACP journal club20070101

Title: Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.

Journal: Clinical pharmacokinetics20070101

Title: The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.

Journal: Clinical pharmacokinetics20070101

Title: Vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapy.

Journal: ACP journal club20070101

Title: Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management.

Journal: Journal of endocrinological investigation20070101

Title: 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.

Journal: The Journal of pharmacology and experimental therapeutics20061201

Title: Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

Journal: Diabetes & vascular disease research20061201

Title: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

Journal: Lancet (London, England)20061111

Title: DPP-4 inhibitors and their potential role in the management of type 2 diabetes.

Journal: International journal of clinical practice20061101

Title: How do different GLP-1 mimetics differ in their actions?

Journal: Current diabetes reports20061101

Title: Exenatide: a novel approach for treatment of type 2 diabetes.

Journal: Southern medical journal20061101

Title: Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.

Journal: Journal of medicinal chemistry20061019

Title: Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Journal: Diabetologia20060901

Title: Targeting postprandial hyperglycemia.

Journal: Metabolism: clinical and experimental20060901

Title: Oral agents for type 2 diabetes reduce HbA1c, are weight neutral.

Journal: Geriatrics20060901

Title: American Diabetes Association--66th scientific sessions. 9-13 June 2006, Washington, DC, USA.

Journal: IDrugs : the investigational drugs journal20060801

Title: Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes.

Journal: Drugs of today (Barcelona, Spain : 1998)20060801

Title: Therapies for the treatment of type 2 diabetes mellitus based on incretin action.

Journal: Minerva endocrinologica20060601

Title: Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme20060601

Title: Molecule of the month. Vildagilptin.

Journal: Drug news & perspectives20060501

Title: Diabetes: assessing the pipeline.

Journal: Atherosclerosis. Supplements20060401

Title: Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.

Journal: Expert opinion on investigational drugs20060401

Title: Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations.

Journal: Pediatric diabetes20060401

Title: Gateways to clinical trials.

Journal: Methods and findings in experimental and clinical pharmacology20060401

Title: [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].

Journal: Medizinische Monatsschrift fur Pharmazeuten20060301

Title: T-cell activation via CD26 and caveolin-1 in rheumatoid synovium.

Journal: Modern rheumatology20060201

Title: 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.

Journal: Journal of medicinal chemistry20060112

Title: Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form.

Journal: Clinical chemistry20060101

Title: Gateways to clinical trials.

Journal: Methods and findings in experimental and clinical pharmacology20060101

Title: Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies.

Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists20060101

Title: Vildagliptin.

Journal: Drugs20060101

Title: Basic Management of Diabetes Mellitus: Practical guidelines.

Journal: The Libyan journal of medicine20060101

Title: Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.

Journal: The Journal of pharmacology and experimental therapeutics20051101

Title: Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.

Journal: Diabetes, obesity & metabolism20051101

Title: Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice.

Journal: European journal of pharmacology20051003

Title: Incretins: what does the future hold?

Journal: Diabetes technology & therapeutics20051001

Title: Alpha cell function in health and disease: influence of glucagon-like peptide-1.

Journal: Diabetologia20050901

Title: Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

Journal: The Journal of clinical endocrinology and metabolism20050801

Title: Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.

Journal: Diabetes care20050801

Title: American Diabetes Association - 65th Scientific Sessions. DDP-IV inhibitors.

Journal: IDrugs : the investigational drugs journal20050801

Title: Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).

Journal: Biochemical pharmacology20050701

Title: Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors.

Journal: Bioorganic & medicinal chemistry letters20050701

Title: Gateways to clinical trials.

Journal: Methods and findings in experimental and clinical pharmacology20050601

Title: Gateways to clinical trials.

Journal: Methods and findings in experimental and clinical pharmacology20050301

Title: Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8.

Journal: Bioorganic & medicinal chemistry letters20050201

Title: Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus.

Journal: Treatments in endocrinology20050101

Title: New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.

Journal: The review of diabetic studies : RDS20050101

Title: Gateways to clinical trials.

Journal: Methods and findings in experimental and clinical pharmacology20041201

Title: Gateways to clinical trials.

Journal: Methods and findings in experimental and clinical pharmacology20041101

Title: 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors.

Journal: Bioorganic & medicinal chemistry letters20040105

Title: 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.

Journal: Journal of medicinal chemistry20030619

Title: Villhauer EB, et al. 1-[[(3-hydroxy-1-adamantyl)aminoacetyl-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003 Jun 19;46(13):2774-89.

Title: Wu YJ, et al. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in associationwith its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism. 2015 Feb;64(2):226-35.

274901-16-5 | Vildagliptin